TMC Life Sciences Bhd (XKLS:0101) Piotroski F-Score: 7 (As of Jul. 02, 2026) — 17% Above Median


XKLS:0101 TMC Life Sciences Bhd XKLS:0101
62 GF Score
Price RM0.45
GF Value RM0.62
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is TMC Life Sciences Bhd Piotroski F-Score?

TMC Life Sciences Bhd XKLS:0101 62 Piotroski F-Score is 7 as of Jul. 02, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates XKLS:0101 with a GF Score™ of 62/100 and a GF Value™ of RM0.62 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 651 Healthcare Providers & Services companies, TMC Life Sciences Bhd ranks better than 88.94% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

TMC Life Sciences Bhd has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for TMC Life Sciences Bhd's Piotroski F-Score or its related term are showing as below:

XKLS:0101' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of TMC Life Sciences Bhd was 9. The lowest was 3. And the median was 6.

TMC Life Sciences Bhd  (XKLS:0101) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


TMC Life Sciences Bhd Piotroski F-Score Related Terms


TMC Life Sciences Bhd Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for TMC Life Sciences Bhd's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TMC Life Sciences Bhd Piotroski F-Score Chart

TMC Life Sciences Bhd Annual Data
Trend May15 May16 Aug17 Aug18 Aug19 Jun21 Jun22 Jun23 Jun24 Jun25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 6.00 8.00 7.00 5.00

TMC Life Sciences Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 6.00 7.00 7.00

XKLS:0101 vs HCA, THC, DVA: Piotroski F-Score Comparison

For the Medical Care Facilities subindustry, TMC Life Sciences Bhd's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TMC Life Sciences Bhd Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, TMC Life Sciences Bhd's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where TMC Life Sciences Bhd's Piotroski F-Score falls into.


XKLS:0101
62GF Score
TMC Life Sciences Bhd XKLS:0101
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 2.423 + 4.413 + 6.56 + 1.758 = RM15.2 Mil.
Cash Flow from Operations was 10.672 + 11.327 + 16.962 + 21.43 = RM60.4 Mil.
Revenue was 93.273 + 100.477 + 103.497 + 89.701 = RM386.9 Mil.
Gross Profit was 58.282 + 63.767 + 65.575 + 57.991 = RM245.6 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(1140.132 + 1132.19 + 1127.1 + 1119.148 + 1110.002) / 5 = RM1125.7144 Mil.
Total Assets at the begining of this year (Mar25) was RM1,140.1 Mil.
Long-Term Debt & Capital Lease Obligation was RM109.2 Mil.
Total Current Assets was RM195.4 Mil.
Total Current Liabilities was RM107.1 Mil.
Net Income was 1.024 + 2.936 + -0.947 + -0.806 = RM2.2 Mil.

Revenue was 74.124 + 81.967 + 80.426 + 89.872 = RM326.4 Mil.
Gross Profit was 49.711 + 55.762 + 54.168 + 59.307 = RM218.9 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1195.919 + 1189.723 + 1178.069 + 1147.075 + 1140.132) / 5 = RM1170.1836 Mil.
Total Assets at the begining of last year (Mar24) was RM1,195.9 Mil.
Long-Term Debt & Capital Lease Obligation was RM153.2 Mil.
Total Current Assets was RM208.8 Mil.
Total Current Liabilities was RM111.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

TMC Life Sciences Bhd's current Net Income (TTM) was 15.2. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

TMC Life Sciences Bhd's current Cash Flow from Operations (TTM) was 60.4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=15.154/1140.132
=0.01329144

ROA (Last Year)=Net Income/Total Assets (Mar24)
=2.207/1195.919
=0.00184544

TMC Life Sciences Bhd's return on assets of this year was 0.01329144. TMC Life Sciences Bhd's return on assets of last year was 0.00184544. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

TMC Life Sciences Bhd's current Net Income (TTM) was 15.2. TMC Life Sciences Bhd's current Cash Flow from Operations (TTM) was 60.4. ==> 60.4 > 15.2 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=109.217/1125.7144
=0.09702017

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=153.184/1170.1836
=0.13090595

TMC Life Sciences Bhd's gearing of this year was 0.09702017. TMC Life Sciences Bhd's gearing of last year was 0.13090595. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=195.367/107.114
=1.82391657

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=208.791/111.663
=1.86983155

TMC Life Sciences Bhd's current ratio of this year was 1.82391657. TMC Life Sciences Bhd's current ratio of last year was 1.86983155. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

TMC Life Sciences Bhd's number of shares in issue this year was 1741.882. TMC Life Sciences Bhd's number of shares in issue last year was 1741.882. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=245.615/386.948
=0.63474937

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=218.948/326.389
=0.67081918

TMC Life Sciences Bhd's gross margin of this year was 0.63474937. TMC Life Sciences Bhd's gross margin of last year was 0.67081918. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=386.948/1140.132
=0.33938877

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=326.389/1195.919
=0.27291899

TMC Life Sciences Bhd's asset turnover of this year was 0.33938877. TMC Life Sciences Bhd's asset turnover of last year was 0.27291899. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+0+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

TMC Life Sciences Bhd has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
TMC Life Sciences Bhd (XKLS:0101) has a Piotroski F-Score of 7 as of Jul. 02, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on TMC Life Sciences Bhd and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, TMC Life Sciences Bhd's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, TMC Life Sciences Bhd ranks #72 out of 651 companies in the Healthcare Providers & Services industry, placing it in the top 11.1%.
Is TMC Life Sciences Bhd's Piotroski F-Score too high?
TMC Life Sciences Bhd's current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. TMC Life Sciences Bhd's value of 7 is 40% above this industry median. Based on the distribution chart, TMC Life Sciences Bhd ranks #72 out of 651 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, TMC Life Sciences Bhd has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TMC Life Sciences Bhd's Piotroski F-Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, TMC Life Sciences Bhd ranks #72 out of 651 companies for Piotroski F-Score. This places TMC Life Sciences Bhd in the top 11% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. TMC Life Sciences Bhd's value of 7 is 40% above this benchmark. Historically, TMC Life Sciences Bhd's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, TMC Life Sciences Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 651 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TMC Life Sciences Bhd's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on TMC Life Sciences Bhd and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TMC Life Sciences Bhd's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMC Life Sciences Bhd stock overvalued right now?
Based on GuruFocus' analysis, TMC Life Sciences Bhd (XKLS:0101) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.62, compared to a current price of RM0.45 — trading 27.4% below its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 40% above the Healthcare Providers & Services industry median of 5.00. TMC Life Sciences Bhd's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For TMC Life Sciences Bhd (XKLS:0101), the current Piotroski F-Score is 7 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TMC Life Sciences Bhd (XKLS:0101) Overvalued in 2026?

Based on GuruFocus' analysis, TMC Life Sciences Bhd stock appears to be undervalued. The current stock price of RM0.45 is trading 27.4% below its estimated GF Value™ of RM0.62. GuruFocus considers TMC Life Sciences Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:0101:

  • Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
  • GF Value™: RM0.62 vs. price of RM0.45 (27.4% below fair value)
  • GF Score™: 62/100 with 3 warning signs
  • Industry Position: 40% above the Healthcare Providers & Services median (#72 of 651)

No single metric tells the full story. See the XKLS:0101 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TMC Life Sciences Bhd Business Description

Address No. 11, PJU 5, Jalan Teknologi, Level 11, Taman Sains, Kota Damansara, Petaling Jaya, SGR, MYS, 47810
TMC Life Sciences Bhd is an investment holding company operating a multi-disciplinary tertiary care center and fertility center in Malaysia. It operates Tropicana Medical Centre, Kota Damansara (TMCKD), a medical center located in Petaling Jaya. Its TMCKD provides healthcare services in various medical/surgical specialties and subspecialties, including anesthesiology, cancer, cardiology, colorectal, dermatology, ENT, fertility, gastroenterology, as well as offers internal medicines and respiratory medicines. Its fertility center provides a range of fertility treatments for couples. The company also operates a women's clinic; provides fertility consultancy, laboratory, and embryology services; and offers pharmacy services and products.
62GF Score

Get the complete analysis for XKLS:0101

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM0.45
Price
RM0.62
GF Value